10-Q: Impact BioMedical Reports Q3 Loss Amid Strategic Shifts

Impact BioMedical reported a significant net loss for Q3 2025, driven by a fair value adjustment on related-party debt, while pursuing strategic acquisitions and a major merger.

Summary

• Impact BioMedical reported a net loss of $17,105,000 for the nine months ended September 30, 2025, a substantial decline from a net income of $2,363,000 in the prior year period.
• The company generated $25,000 in biotech retail sales for the nine months ended September 30, 2025, compared to no revenue in the same period of 2024, primarily from its newly acquired Celios air purification technology.
• Operating loss increased to $3,112,000 for the nine months ended September 30, 2025, from $2,522,000 in the prior year.
• Cash and cash equivalents significantly decreased to $12,000 as of September 30, 2025, from $1,999,000 at December 31, 2024.
• Total liabilities surged to $27,061,000 from $13,053,000, largely due to an increase in the related-party note payable.
• Stockholders' equity shifted to a deficit of $8,853,000 as of September 30, 2025, from a positive equity of $7,237,000 at December 31, 2024.
• Net cash used in operating activities increased to $1,989,000 for the nine months ended September 30, 2025, from $1,868,000 in the prior year.
• The company completed an initial public offering on September 16, 2024, raising $3,726,000 net of issuance costs.
• Acquired certain assets of DSS Pure Air, Inc., including intellectual property for the Celios air purification system, for $1,150,000 paid in common stock on February 25, 2025.
• Subsequent to the quarter, the related-party note payable of $22,881,000 was converted into 31,939,778 shares of common stock on October 16, 2025.
• Also, 60,496,041 shares of Series A Convertible Preferred Stock were converted into common stock on October 16, 2025.
• A Merger and Share Exchange Agreement with Dr Ashleys Limited and its subsidiaries is anticipated to close in Q1 2026.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, marked by substantial net losses, negative cash flow from operations, and a going concern warning. While there are strategic initiatives like new product acquisitions and a pending merger, the current financial performance and liquidity position are very weak. The subsequent debt-to-equity conversion and preferred stock conversion improve the balance sheet structure but do not address the underlying operational cash burn or profitability issues.

Positives

• Generated initial biotech retail sales of $25,000 for the nine months ended September 30, 2025, from the new Celios air purification product line, compared to no revenue in the prior year.
• Successfully completed an Initial Public Offering (IPO) on September 16, 2024, raising $3,726,000 net of issuance costs, providing capital for operations.
• Acquired intellectual property for the Celios air purification system, expanding the product portfolio and revenue streams.
• Secured licensing agreements for Linebacker and Equivir/Equivir G technologies with ProPhase Laboratories for worldwide development and commercialization, offering potential future milestone and royalty payments.
• Laetose technology has a unique composition patent allowed in the United States, with patents pending globally, indicating strong intellectual property protection.
• The conversion of the $22,881,000 related-party note payable into common stock and the conversion of Series A Preferred Stock significantly reduced debt and simplified the capital structure post-quarter end.

Negatives

• Reported a significant net loss of $17,105,000 for the nine months ended September 30, 2025, a substantial deterioration from a net income of $2,363,000 in the prior year.
• Cash and cash equivalents declined sharply to $12,000 as of September 30, 2025, from $1,999,000 at December 31, 2024, indicating a critical liquidity position.
• Total liabilities more than doubled to $27,061,000 from $13,053,000, primarily due to the related-party note payable, before its subsequent conversion.
• Stockholders' equity shifted to a deficit of $8,853,000, reflecting accumulated losses.
• Net cash used in operating activities increased to $1,989,000, indicating a higher cash burn rate.
• Research and development costs decreased by 40% to $230,000, potentially signaling a slowdown in new technology development or a pause in existing projects.
• Sales and marketing costs decreased by 95% to $22,000, which could hinder commercialization efforts for new products.
• Professional fees increased by 177% to $868,000, reflecting higher costs associated with business plan execution and M&A due diligence.
• The company recorded a $25,093,000 goodwill impairment as of December 31, 2024, indicating a significant write-down of previously acquired assets' value.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• The company has not generated significant revenues from operations to date and cannot guarantee future business success.
• Business operations are subject to risks inherent in establishing a new business enterprise, including possible delays in research, testing, and marketing efforts.
• The effectiveness of disclosure controls and procedures was not confirmed, indicating potential risks in financial reporting and information communication.
• Future cash flow projections for long-lived assets are uncertain, and failure to generate forecasted revenue from new products could result in non-cash impairment losses.
• Reliance on external partners for commercialization and distribution means potential profits are contingent on their success and milestone/royalty payments.

Future Outlook

The company anticipates closing a Merger and Share Exchange Agreement with Dr Ashleys Limited and its subsidiaries during the first quarter of 2026. Management intends to continue as a going concern by monetizing its intellectual properties and tightly controlling operating costs. The company continually evaluates additional proprietary technologies for potential patent filings and commercialization.

Management Comments

• "We continually search for, and evaluate, other potential new offerings to add to our portfolio."
• "Our business model includes partnering and potentially direct sales for commercialization and distribution."
• "Managements plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs."
• "There is no assurance that anyone, or all, of these [emerging technologies] will result in a material transaction and this is exemplary of consistent and ongoing search and discovery efforts within Impact Biomedical Inc."

Industry Context

Impact BioMedical operates in the highly competitive and capital-intensive biopharmaceutical, wellness, and technology licensing sectors. Its strategy of leveraging intellectual property through licensing and co-development with external partners is common for early-stage biotech firms seeking to mitigate R&D costs and accelerate commercialization. The focus on polyphenols for oncology, inflammatory, and neurological disorders, as well as functional ingredients for caloric reduction and antiviral effects, aligns with growing consumer and medical interest in natural compounds and preventative health. The entry into indoor air quality products with Celios also taps into increasing health and environmental consciousness. However, the company's limited revenue and significant losses highlight the challenges of commercializing novel technologies in these industries.

Comparison to Industry Standards

• The company's revenue of $25,000 for nine months is extremely low compared to established biopharmaceutical or consumer health companies, indicating it is still in a very early commercialization phase.
• The substantial net loss of $17.1 million and negative stockholders' equity are typical for pre-revenue or early-revenue biotech companies heavily investing in R&D and IP, but the magnitude raises significant going concern issues.
• The strategy of licensing technologies (e.g., Linebacker, Equivir to ProPhase Laboratories) is a standard approach for small biotech firms to monetize IP without incurring full development and commercialization costs, similar to models used by companies like Moderna (early licensing deals) or smaller drug discovery firms.
• The acquisition of the Celios air purification system and its initial retail sales represent a diversification into a consumer product market, which can offer quicker revenue generation compared to lengthy drug development cycles, but also faces intense competition from established brands like Dyson or Blueair.
• The significant goodwill impairment of $25 million in 2024 suggests that prior acquisitions or investments did not meet expected valuation, which is a red flag for asset management and valuation practices, contrasting with more stable asset valuations seen in mature industry players.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings, but may become involved in litigation arising in the ordinary course of business, which could have an adverse impact.

Related Party Transactions

• Revolving Promissory Note with DSS, a related party, with an outstanding balance of $22,881,000 as of September 30, 2025, which was subsequently converted into common stock.
• Acquisition of certain assets owned by DSS Pure Air, Inc., a related party, for $1,150,000 paid by 545,024 shares of common stock on February 25, 2025.
• General and administrative costs incurred by DSS on behalf of the Company, amounting to approximately $238,000 for the nine months ended September 30, 2025, and $26,000 per month starting October 2024.
• DSS BioHealth Security, Inc. (a related party) converted its 60,496,041 shares of Series A Convertible Preferred Stock into common stock on October 16, 2025.

Stakeholder Impact

• **Shareholders**: Significant dilution from the conversion of related-party debt and preferred stock into common shares. The going concern warning and continued losses pose a high risk to investment value. The pending merger could offer future upside or further dilution depending on terms.
• **Employees**: Increased headcount and bonus accruals suggest some growth in personnel, but the overall financial instability and cost control measures could create uncertainty.
• **Customers**: The introduction of the Celios air purification system provides a new product offering, but the company's limited sales and marketing efforts might affect market penetration and customer awareness.
• **Creditors**: The conversion of the significant related-party note payable into equity reduces the company's debt burden, which is positive for remaining creditors, but the overall financial health remains a concern.
• **Suppliers**: The increase in accounts payable and accrued expenses, despite some payments, indicates ongoing operational costs that need to be managed carefully.

Next Steps

• Monetization of intellectual properties.
• Tightly controlling operating costs.
• Closing of the Merger and Share Exchange Agreement with Dr Ashleys Limited and its subsidiaries, anticipated in Q1 2026.
• Continued search and evaluation of additional proprietary technologies for patent filings and commercialization.

Key Dates

Recommendation

The company exhibits severe financial distress, marked by a substantial net loss of $17.1 million, a shift to negative stockholders' equity, and critically low cash reserves of $12,000. The 'going concern' warning is a major red flag. While the subsequent conversion of related-party debt and preferred stock into equity improves the balance sheet structure, it does not address the fundamental issues of operational cash burn and lack of significant revenue generation. The decrease in R&D and marketing spend, coupled with rising professional fees, suggests a company struggling to balance growth initiatives with financial stability. The ineffectiveness of disclosure controls further undermines investor confidence. The pending merger with Dr Ashleys Limited introduces uncertainty rather than immediate stability. Given the high risk, poor financial performance, and significant dilution, a seasoned investor would likely recommend a strong sell.

Keywords

Biomedical, Biopharmaceuticals, Healthcare, Wellness, SEC Filing, 10-Q, Biotech, Intellectual Property, Licensing, Oncology, Inflammatory Disorders, Neurology, Air Purification, Laetose, Equivir, Linebacker, Functional Fragrance Formulation, IPO, Related Party Transactions, Going Concern